Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 05 - 02 tags : Treatment save search
Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis Scheduled for June 17, 2022
Published: 2022-05-02 (Crawled : 21:00) - biospace.com/
ACAD | $16.82 -1.47% -1.49% 3.5M
|
Health Technology
|
| O: -1.41%
H: 7.65%
C: 7.48%
nuplazid treatment fda drug disease application resubmission alzheimer’s review alzheimer's
Soleno Therapeutics Announces Presentation of Long-Term Hyperphagia and Behavioral Data in Patients Receiving DCCR for Treatment of Prader-Willi Syndrome
Published: 2022-05-02 (Crawled : 21:00) - biospace.com/
SLNO 4 | $37.53 1.02% 1.01% 190K
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: -4.95%
treatment therapeutics presentation
Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Published: 2022-05-02 (Crawled : 16:00) - biospace.com/
SRZN | $9.33 9.39% 2K
|
|
| O: 1.56%
H: 1.53%
C: 0.0%
szn-413 treatment research potential diabetic
Vaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimer’s Disease
Published: 2022-05-02 (Crawled : 13:20) - biospace.com/
VAXX | $0.4761 2.43% 2.37% 290K
|
|
| O: -6.84%
H: 5.72%
C: 5.72%
ub-311 treatment fda designation disease alzheimer’s fast track designation alzheimer's
Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis, and Expects to File a New Drug Application This Year
Published: 2022-05-02 (Crawled : 13:20) - biospace.com/
TARS | $32.405 -1.36% -1.37% 630K
|
Health Technology
|
| O: -7.69%
H: 0.47%
C: -17.01%
tp-03 treatment drug topline application trial positive phase 3
Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
Published: 2022-05-02 (Crawled : 13:20) - biospace.com/
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
|
| O: -3.41%
H: 0.0%
C: 0.0%
vx-880 treatment trial diabetes phase 1
Axsome Therapeutics Receives FDA Complete Response Letter for New Drug Application for AXS-07 for the Acute Treatment of Migraine
Published: 2022-05-02 (Crawled : 12:20) - biospace.com/
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
axs-07 treatment fda drug application therapeutics response migraine
Physicians Foresee an Alzheimer's Disease Treatment Revolution Supported by Advanced Testing Tools, New Quest Diagnostics Report Finds
Published: 2022-05-02 (Crawled : 12:00) - prnewswire.com
DGX | $128.44 2.01% 0.0% 1.6M
|
Health Services
|
| O: -1.48%
H: 0.68%
C: -1.12%
treatment disease report alzheimer's diagnostics diagnostic test alzheimer’s
IDEAYA Biosciences Receives Orphan Drug Designation for Darovasertib, a PKC Inhibitor, for the Treatment of Uveal Melanoma
Published: 2022-05-02 (Crawled : 11:00) - biospace.com/
IDYA | $37.1 -1.38% -1.4% 730K
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
treatment designation drug
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)
Published: 2022-05-02 (Crawled : 11:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: -1.12%
H: 0.0%
C: 0.0%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -1.95%
H: 1.37%
C: 0.49%
treatment drug application therapeutics food potential submission major depressive disorder
Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Published: 2022-05-02 (Crawled : 09:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -3.78%
H: 0.8%
C: 0.33%
uplizna treatment approval therapeutics
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.